PACB Stock Recent News
PACB LATEST HEADLINES
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close.
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service.
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time.
PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down.
New sequencing approach resolves the genetic complexity of a rare Mendelian condition New sequencing approach resolves the genetic complexity of a rare Mendelian condition
MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS) at the University of Saskatchewan (USask) as the first Revio PacBio Certified Service Provider (CSP) in Canada.
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.